Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

PubWeight™: 34.34‹?› | Rank: Top 0.01% | All-Time Top 10000

🔗 View Article (PMID 9742977)

Published in Lancet on September 12, 1998

Associated clinical trials:

HbA1c Variability in Type II Diabetes | NCT02879409

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study | NCT02613897

Financial Incentives and Text Messaging to Improve African American Womens' Glycemic Control (FRIENDS-Text) | NCT02384265

Efficacy Study of Metformin Glycinate on Postprandial Lipemia | NCT02064881

Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes (COMET) | NCT01386671

The Effects of Metformin on Blood Vessel Structure and Function | NCT00105066

Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome (PRIME) | NCT03031821

Metformin Pharmacology in Human Cancers: A Proof of Principle Study | NCT03477162

TELE-DD Project: a Joint Prospective Cohort Study and Nurse-led Randomised Controlled Trial on Treatment Adherence in Patients With Type 2 Diabetes and Clinical Depression (TELE-DD) | NCT04097483

EndoBarrier System Pivotal Trial(Rev B) (STEP-1) | NCT04101669

Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes (COMETII) | NCT04943692

Articles citing this

(truncated to the top 100)

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06

Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85

Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28

Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05

Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66

Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78

A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 8.70

Utility of hemoglobin A1c in predicting diabetes risk. J Gen Intern Med (2004) 5.97

Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med (2003) 5.87

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ (2011) 5.77

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care (2008) 5.43

The metabolic syndrome. Endocr Rev (2008) 5.33

Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care (2013) 4.85

The relative importance of physician communication, participatory decision making, and patient understanding in diabetes self-management. J Gen Intern Med (2002) 4.79

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med (2011) 4.76

The barrier of hypoglycemia in diabetes. Diabetes (2008) 4.50

Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA (2014) 4.50

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet (2010) 4.42

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 4.33

One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring) (2009) 4.08

Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med (2012) 4.02

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007) 3.95

Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care (2005) 3.93

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ (2006) 3.68

Diabetes in older adults: a consensus report. J Am Geriatr Soc (2012) 3.63

Diabetes in older adults. Diabetes Care (2012) 3.62

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med (2008) 3.54

Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48

Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study. Clin Chem (2005) 3.15

Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: rationale and design. J Am Med Inform Assoc (2001) 3.06

A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus. J Am Med Inform Assoc (2005) 3.01

Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study. BMJ (2000) 2.96

Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes (2015) 2.87

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care (2012) 2.84

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84

Vascular endothelial growth factor in eye disease. Prog Retin Eye Res (2008) 2.73

Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes (2011) 2.72

The treatment of type 2 diabetes. Dtsch Arztebl Int (2014) 2.66

Contraindications to the use of metformin. BMJ (2003) 2.59

The failings of NICE. Reply from chairman of NICE. BMJ (2001) 2.55

Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ (2010) 2.54

Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care (2011) 2.54

Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ (2011) 2.49

Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation (2008) 2.48

Practice-linked online personal health records for type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med (2008) 2.47

AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest (2013) 2.44

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ (2009) 2.42

Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am Heart J (2008) 2.40

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care (2008) 2.33

Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord (2008) 2.31

Active care management supported by home telemonitoring in veterans with type 2 diabetes: the DiaTel randomized controlled trial. Diabetes Care (2009) 2.31

Insulin resistance and atherosclerosis. J Clin Invest (2006) 2.27

Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ (2005) 2.24

Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ (2002) 2.24

Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int (2014) 2.22

Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res (2008) 2.19

Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med (2012) 2.18

Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med (2014) 2.17

Changing physical activity behavior in type 2 diabetes: a systematic review and meta-analysis of behavioral interventions. Diabetes Care (2012) 2.16

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10

Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation (2009) 2.09

2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J (2016) 2.09

AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J (2009) 2.09

The Vermont Diabetes Information System (VDIS): study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices. Clin Trials (2004) 2.05

Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care (2014) 2.04

2011 clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J (2011) 2.01

American Geriatrics Society identifies five things that healthcare providers and patients should question. J Am Geriatr Soc (2013) 1.99

Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest (2001) 1.97

Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements. J Diabetes Sci Technol (2009) 1.93

Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int (2011) 1.91

Impact of a diabetes certificate program on PharmD students' knowledge and skills. Am J Pharm Educ (2007) 1.90

Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc (2009) 1.88

Potential of surgery for curing type 2 diabetes mellitus. Ann Surg (2002) 1.88

Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med (2012) 1.85

Geographic variation in pharmacotherapy decisions for U.S. Medicare enrollees with diabetes. J Diabetes Complications (2012) 1.84

Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes (2009) 1.83

Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail (2010) 1.82

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ (2006) 1.80

Trends in the prevalence and management of diagnosed type 2 diabetes 1994-2001 in England and Wales. BMC Fam Pract (2005) 1.80

The blooming of the French lilac. J Clin Invest (2001) 1.80

Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79

Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther (2011) 1.79

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care (2008) 1.79

Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care (2012) 1.78

GPs' perspectives of type 2 diabetes patients' adherence to treatment: A qualitative analysis of barriers and solutions. BMC Fam Pract (2005) 1.78

A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care (2011) 1.78

Defining and characterizing the progression of type 2 diabetes. Diabetes Care (2009) 1.77

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ (2009) 1.74

TCF7L2 variants associate with CKD progression and renal function in population-based cohorts. J Am Soc Nephrol (2008) 1.71

Molecular mechanism of action of metformin: old or new insights? Diabetologia (2013) 1.71

Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail (2009) 1.70

Use of chronic care model elements is associated with higher-quality care for diabetes. Ann Fam Med (2007) 1.68

Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine. Diabetes Care (2015) 1.67

Metformin-associated lactic acidosis in an intensive care unit. Crit Care (2008) 1.66